DAXOR CORP 10-Q Summary: Quarter Ended March 31, 1995
Business Context and Reporting Period
This Form 10-Q covers the three-month period ended March 31, 1995. DAXOR Corporation operates a blood banking division and is developing a Blood Volume Analyzer (BVA-100). The company's financial profile is heavily influenced by a significant portfolio of marketable securities, which are classified as "Available-For-Sale" under FASB No. 115.
Key Financial Metrics
| Metric | Q1 1995 | Q1 1994 |
|---|---|---|
| Total Revenues | $1,246,502 | $1,111,932 |
| Operating Revenues | $503,480 | $486,175 |
| Net Income | $569,982 | $512,155 |
| Net Income Per Share | $0.11 | $0.10 |
| Cash and Equivalents (End of Period) | $44,284 | $47,075 |
| Marketable Securities (Fair Value) | $33,379,511 | N/A |
| Loans Payable | $2,727,117 | N/A |
| Total Assets | $35,173,627 | N/A |
Liquidity: The company reported a net decrease in cash of $15,678 for the quarter. Operating cash flow was negative at $(20,162), while investing activities provided $11,488 in net cash, primarily driven by the sale of investments offset by loan repayments.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased by approximately 12.1% year-over-year, driven largely by a 175% increase in gains on the sale of securities ($198,038 vs. $71,684) and higher dividend income.
- Operating Stability: Operating revenues from the blood banking division remained relatively flat, increasing only slightly from $486,175 to $503,480.
- Debt Reduction: Loans payable decreased significantly from $3,864,605 at December 31, 1994, to $2,727,117 at March 31, 1995, reflecting a repayment of approximately $1.14 million in broker loans.
- Unrealized Gains: The adoption of FASB No. 115 resulted in a net unrealized gain on securities of $6,063,620 (22.2% of cost) as of March 31, 1995, up from $5,293,194 at the end of 1994.
Outlook, Risks, and Management Commentary
Outlook: Management states that operating revenues have remained flat as the company focuses on obtaining additional licenses for its blood banking division. Significant additional revenues are not expected until the Blood Volume Analyzer and its isotope receive approval for medical use.
Liquidity Position: The company asserts it has adequate resources to continue development and marketing of the BVA-100 and to sustain its current blood bank operations. However, management notes that a full-scale, nationwide expansion of the blood banking operation would require additional capital.
Risks: The company's financial results are heavily dependent on the performance of its investment portfolio. While the portfolio has generated significant unrealized gains, the core operating business has shown limited growth pending regulatory approvals.
Investor Verification Checklist
- Verify the regulatory status and approval timeline for the Blood Volume Analyzer (BVA-100) and its isotope.
- Confirm the composition and risk profile of the $33.4 million marketable securities portfolio, which drives the majority of the company's equity value.
- Assess the sustainability of the negative operating cash flow ($20,162) relative to the company's cash reserves ($44,284).
- Review the terms of the $2.6 million bank loan and $127,117 in margin debt to understand collateral requirements and interest rate exposure.